Medical News Today -
13 Dec 2013 12:00
A large landmark study funded by Cancer Research UK has found that the breast cancer drug anastrozole can halve the chances of developing the disease in high-risk women.The results of the IBIS II trial, led by Queen Mary University of London and published online in the The Lancet this week, show that in nearly 4,000 post-menopausal women at high risk of breast cancer, taking anastrozole for 5 years cut cases by 53%, compared with a placebo.
Share this Article